Engineered lysine acyltransferases and methods of use thereof
AssigneeWilliam Marsh Rice University
InventorsIsaac HILTON, Jacob GOELL, Shriya SHAH, Sunghwan KIM
Life of this patent
Estimating the term…
Abstract
The present disclosure provides engineered lysine acyltransferases, such as acetyltransferases (e.g., p300 or CBP), comprising one or more mutations which decrease cellular toxicity as compared to endogenous lysine acyltransferase, such as acetyltransferase (e.g., p300 or CBP). Further provided are methods for the use of the engineered lysine acyltransferase, such as acetyltransferase (e.g., p300 or CBP), for activating gene expression and cell therapy.
Claims20
A polypeptide comprising an engineered human lysine acyltransferase or effector domain thereof comprising at least one amino acid mutation in the acyl-CoA binding site.
The polypeptide of any one of claims 1-5, wherein the lysine acyltransferase, lysine acetyltransferase (KAT), or lysine crotonyltransferase is fused to (a) Tetracycline repressor (TetR) protein, (b) a (Clustered Regularly Interspaced Short Palindromic Repeats associated) Cas protein, (c) a Zinc finger or TALE protein, and/or (d) a reporter.
A DNA targeting system comprising the fusion protein of 8 or 9 and at least one guide RNA (gRNA).
Dependencies are inferred from the claim text.